AR042152A1 - Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos - Google Patents
Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticosInfo
- Publication number
- AR042152A1 AR042152A1 ARP030104411A ARP030104411A AR042152A1 AR 042152 A1 AR042152 A1 AR 042152A1 AR P030104411 A ARP030104411 A AR P030104411A AR P030104411 A ARP030104411 A AR P030104411A AR 042152 A1 AR042152 A1 AR 042152A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- compounds
- diabetic patients
- dihydroxibencesulphonic
- medicinal product
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 230000002102 hyperpolarization Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000004089 microcirculation Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Uso de los componentes 2,5-dihidroxibencenosulfónicos para la fabricación de un medicamento para ser administrado por via oral destinado a la regulación de la síntesis del óxido nítrico (ON) y/o regulación del FHDE (factor hiperpolarizador derivado del endotelio) en el endotelio de pacientes diabéticos, administrándose el medicamento a una dosis diaria de <500 mg de compuestos 2,5-dihidroxibencenosulfónicos. Se utiliza para tratar retinopatias, disfunción eréctil, trastornos renales y de microcirculación coronaria, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200202755A ES2208124B1 (es) | 2002-11-29 | 2002-11-29 | Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042152A1 true AR042152A1 (es) | 2005-06-08 |
Family
ID=32405966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104411A AR042152A1 (es) | 2002-11-29 | 2003-12-01 | Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060135611A1 (es) |
| EP (1) | EP1596850A1 (es) |
| JP (1) | JP2006509778A (es) |
| CN (1) | CN1744891A (es) |
| AR (1) | AR042152A1 (es) |
| AU (1) | AU2003289914A1 (es) |
| BR (1) | BR0316134A (es) |
| CA (1) | CA2507750A1 (es) |
| ES (1) | ES2208124B1 (es) |
| MX (1) | MXPA05005719A (es) |
| NO (1) | NO20053032L (es) |
| RU (1) | RU2005120634A (es) |
| WO (1) | WO2004050075A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006080481A1 (ja) * | 2005-01-31 | 2006-08-03 | Kyorin Pharmaceutical Co., Ltd. | マルチプルユニット型経口徐放性製剤及びその製造方法 |
| FR2902096B1 (fr) * | 2006-06-13 | 2011-03-18 | Rhodia Recherches & Tech | Procede de preparation de dihydroxybenzenedisulfonates metalliques |
| US9198886B2 (en) * | 2006-08-16 | 2015-12-01 | Pedro Cuevas Sánchez | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases |
| US20080182513A1 (en) * | 2007-01-29 | 2008-07-31 | Hassan Amer A | High Frequency Communications |
| CN102038671B (zh) * | 2010-06-29 | 2012-07-04 | 辽宁思百得医药科技有限公司 | 包含左卡尼汀和羟苯磺酸盐的药物组合物 |
| CN114601816B (zh) * | 2021-10-09 | 2022-09-02 | 北京惠之衡生物科技有限公司 | 一种羟苯磺酸钙胶囊组合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608045B1 (fr) * | 1986-12-12 | 1990-03-02 | Chauvin Laboratoires | Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome |
| FR2656525A1 (fr) * | 1989-12-29 | 1991-07-05 | Delalande Sa | Formes d'administration de medicament a liberation controlee et leur procede de fabrication. |
| DE4413350A1 (de) * | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
| AU715600B2 (en) * | 1996-04-03 | 2000-02-03 | Laboratorios Del Dr. Esteve, S.A. | Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin |
| DE10016356B4 (de) * | 2000-04-03 | 2007-06-21 | Beisel, Günther | Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung |
-
2002
- 2002-11-29 ES ES200202755A patent/ES2208124B1/es not_active Expired - Fee Related
-
2003
- 2003-11-29 AU AU2003289914A patent/AU2003289914A1/en not_active Abandoned
- 2003-11-29 BR BR0316134-0A patent/BR0316134A/pt not_active IP Right Cessation
- 2003-11-29 CN CNA2003801093431A patent/CN1744891A/zh active Pending
- 2003-11-29 EP EP03782253A patent/EP1596850A1/en not_active Ceased
- 2003-11-29 JP JP2004556233A patent/JP2006509778A/ja active Pending
- 2003-11-29 MX MXPA05005719A patent/MXPA05005719A/es not_active Application Discontinuation
- 2003-11-29 WO PCT/EP2003/013469 patent/WO2004050075A1/en not_active Ceased
- 2003-11-29 RU RU2005120634/04A patent/RU2005120634A/ru not_active Application Discontinuation
- 2003-11-29 CA CA002507750A patent/CA2507750A1/en not_active Abandoned
- 2003-11-29 US US10/536,782 patent/US20060135611A1/en not_active Abandoned
- 2003-12-01 AR ARP030104411A patent/AR042152A1/es not_active Application Discontinuation
-
2005
- 2005-06-20 NO NO20053032A patent/NO20053032L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2208124B1 (es) | 2005-10-01 |
| WO2004050075A1 (en) | 2004-06-17 |
| AU2003289914A1 (en) | 2004-06-23 |
| JP2006509778A (ja) | 2006-03-23 |
| US20060135611A1 (en) | 2006-06-22 |
| ES2208124A1 (es) | 2004-06-01 |
| NO20053032L (no) | 2005-06-20 |
| MXPA05005719A (es) | 2005-08-16 |
| EP1596850A1 (en) | 2005-11-23 |
| CA2507750A1 (en) | 2004-06-17 |
| CN1744891A (zh) | 2006-03-08 |
| BR0316134A (pt) | 2005-10-11 |
| RU2005120634A (ru) | 2006-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| AR022085A1 (es) | Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| BR9909672A (pt) | uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão | |
| CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
| NO20055880L (no) | Memantin orale doseringsformer | |
| AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| AR019053A1 (es) | Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| AR036312A1 (es) | Composicion farmaceutica | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| ES2119748T3 (es) | Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. | |
| AR042153A1 (es) | Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
| PE20030830A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
| AR037356A1 (es) | Forma de dosificacion oral de una prodroga de sulfonamida | |
| DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| CL2025001901A1 (es) | Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |